Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Nvidia falls after rallying Thursday, Marvell’s latest earnings fail to impress Wall Street, and Gap and American Eagle ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

In a 1 a.m. Eastern time press release, Regeneron said one Phase 3 trial of itepekimab, in adult former smokers with COPD, met the primary target by showing significant reduction of 27% in the sudden ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

DSG Capital Advisors bought 847 Regeneron shares, valuing their stake at around $603,000, joining a long list of eager ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

Williams Jones Wealth Management reduced its Regeneron Pharmaceuticals holdings by 39.4% in the fourth quarter, unloading 715 ...

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...